Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 398

The DOI matches its Crossref record; 25 of the 25 references it cites were found in a registry or an index.

Golimumab, a human anti–tumor necrosis factor α monoclonal antibody, injected subcutaneously every four weeks in methotrexate‐naive patients with active rheumatoid arthritis: Twenty‐four–week results of a phase III, multicenter, randomized, double‐blind, placebo‐controlled study of golimumab before methotrexate as first‐line therapy for early‐onset rheumatoid arthritis

Open access
Emery, Paul, Fleischmann, Roy M., Moreland, Larry W., Hsia, Elizabeth C., Strusberg, Ingrid, Durez, Patrick, Nash, Peter, Amante, Eric Jason B., Churchill, Melvin, Park, Won, Pons‐Estel, Bernardo Antonio, Doyle, Mittie K., Visvanathan, Sudha, Xu, Weichun, Rahman, Mahboob U.·2009·Arthritis & Rheumatism

Abstract

Objective: To assess the safety and efficacy of golimumab in methotrexate (MTX)–naive patients with active rheumatoid arthritis (RA). Methods: MTX‐naive patients with RA (n = 637) were randomized to receive placebo plus MTX (group 1), golimumab 100 mg plus placebo (group 2), golimumab 50 mg plus MTX (group 3), or golimumab 100 mg plus MTX (group 4). Subcutaneous injections of golimumab or placebo were administered every 4 weeks. The dosage of MTX/placebo capsules started at 10 mg/week and escalated to 20 mg/week. The primary end point, the proportion of patients meeting the American College of Rheumatology 50% improvement criteria (achieving an ACR50 response) at week 24, required significant differences between groups 3 and 4 combined (combined group) versus group 1 and significant differences in a pairwise comparison (group 3 or group 4 versus group 1). Results: An intent‐to‐treat (ITT) analysis of the ACR50 response at week 24 did not show a significant difference between the combined group and group 1 (38.4% and 29.4%, respectively; P = 0.053), while a post hoc modified ITT analysis (excluding 3 untreated patients) of the ACR50 response showed statistically significant differences between the combined group and group 1 (38.5% versus 29.4%; P = 0.049) and between group 3 (40.5%; P = 0.038) but not group 4 (36.5%; P = 0.177) and group 1. Group 2 was noninferior to group 1 for the ACR50 response at week 24 (33.1%; 95% confidence interval lower bound −5.2%; predefined delta value for noninferiority −10%). The combination of golimumab plus MTX demonstrated a significantly better response compared with placebo plus MTX in most other efficacy parameters, including response/remission according to the Disease Activity Score in 28 joints. Serious adverse events occurred in 7%, 3%, 6%, and 6% of patients in groups 1, 2, 3, and 4, respectively. Conclusion: Although the primary end point was not met, the modified ITT analysis of the primary end point and other prespecified efficacy measures demonstrated that the efficacy of golimumab plus MTX is better than, and the efficacy of golimumab alone is similar to, the efficacy of MTX alone in reducing RA signs and symptoms in MTX‐naive patients, with no unexpected safety concerns.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1002/art.24638

Cites

25 of 25 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 25 references

Research works printed but not linked: 5

  1. Shealy D, 2007, Characterization of golimumab (CNTO 148), a novel fully human monoclonal antibody specific for human TNFα, Ann Rheum Dis, 66, ii151
  2. Schiff M, 1999, Comparison of ACR response, numeric ACR, and ACR AUC as measures of clinical improvement in RA clinical trials, Arthritis Rheum, 42, S81
  3. Van Riel PL, 2000, EULAR handbook of clinical assessments in rheumatoid arthritis, 40
  4. Mader R, 2007, Optimizing treatment with biologics, J Rheumatol, 34, S16
  5. 10.1056/NEJM200011303432201 · DOI · Paper page

Cited by

See all 398

Metadata

Authors
Emery, P., Fleischmann, R. M., Moreland, L. W., Hsia, E. C., Strusberg, I., Durez, P., Nash, P., Amante, E. J. B., Churchill, M., Park, W., Pons‐Estel, B. A., Doyle, M. K., Visvanathan, S., Xu, W., & Rahman, M. U.
Venue
Arthritis & Rheumatism
Publisher
Wiley
Published
2009-07-30
Volume
60
Issue
8
Pages
2272-2283
ISSN
  • 0004-3591 (ISSN-L)
  • 1529-0131
OpenAlex
W1966756501
Cited by
398
References
25
FWCI
22.62
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Golimumab, a human anti–tumor necrosis factor α monoclonal antibody, injected subcutaneously every four weeks in methotrexate‐naive patients with active rheumatoid arthritis: Twenty‐four–week results of a phase III, multicenter, randomized, double‐blind, placebo‐controlled study of golimumab before methotrexate as first‐line therapy for early‐onset rheumatoid arthritis. https://app.cochat.ai/papers/10.1002/art.24638
The paper
Emery, P., Fleischmann, R. M., Moreland, L. W., Hsia, E. C., Strusberg, I., Durez, P., Nash, P., Amante, E. J. B., Churchill, M., Park, W., Pons‐Estel, B. A., Doyle, M. K., Visvanathan, S., Xu, W., & Rahman, M. U. (2009). Golimumab, a human anti–tumor necrosis factor α monoclonal antibody, injected subcutaneously every four weeks in methotrexate‐naive patients with active rheumatoid arthritis: Twenty‐four–week results of a phase III, multicenter, randomized, double‐blind, placebo‐controlled study of golimumab before methotrexate as first‐line therapy for early‐onset rheumatoid arthritis. Arthritis & Rheumatism. https://doi.org/10.1002/art.24638

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.